[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341117-105":59,"doc-detail-341117-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","human-patient-derived-organoids-an-emerging-precision-medicine-model-for-gastrointestinal-cancer-research","Human patient derived organoids - an emerging precision medicine model for gastrointestinal cancer research","","Gastrointestinal cancers remain a major global cause of incidence and mortality, with limited effective treatments driven by inadequate preclinical models. Tumor patient-derived organoids (PDOs) provide a novel 3D in vitro platform generated from patient tumor tissue, retaining key biological features and enabling co-culture to reproduce aspects of the in vivo tumor microenvironment. The review surveys in vitro tumor models, PDO derivation, and applications in gastrointestinal cancers, including CRISPR/Cas9 gene editing, microenvironment simulation, drug screening, drug development, and personalized medicine, while addressing ethical issues and current clinical challenges.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/human-patient-derived-organoids-an-emerging-precision-medicine-model-for-gastrointestinal-cancer-research/341117/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/human-patient-derived-organoids-an-emerging-precision-medicine-model-for-gastrointestinal-cancer-research/341117.png","ImageObject",300,407,{"name":92,"@type":93},"Emma Wilson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are gastrointestinal cancers difficult to treat with current approaches?","Question",{"text":112,"@type":113},"Many gastrointestinal cancer cases have a poor prognosis and lack effective treatments, partly because established preclinical models are not sufficiently appropriate for developing safe and potent therapies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What are tumor patient-derived organoids (PDOs) and what do they enable?",{"text":117,"@type":113},"PDOs are derived from patients’ tumor tissue and cultured as 3D architectures. They preserve key biological characteristics of the original tumor and can recreate elements of the tumor microenvironment through co-culture.",{"name":119,"@type":110,"acceptedAnswer":120},"How are PDOs used alongside CRISPR/Cas9 and for drug-related research?",{"text":121,"@type":113},"The review highlights applications of PDO technology in gastrointestinal cancers, including combining with CRISPR/Cas9 gene editing, simulating the tumor microenvironment, and supporting drug screening and drug development.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341117,1790991776,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","TYPE Review  \nPUBLISHED 04 April 2024  \nDOI 10.3389/fcell.2024.1384450  \nOPEN ACCESS  \nEDITED BY  \nOcéane C. B. Martin,  \nUniversité de Bordeaux, France  \nREVIEWED BY  \nGarima Kaushik,  \nChampions Oncology, Inc., United States Xiaolei Li,  \nUniversity of Pennsylvania, United States  \n*CORRESPONDENCE  \nZhihong Ma,  \n [mazhihong@hzhospital.com](mazhihong@hzhospital.com)  \nRECEIVED 09 February 2024  \nACCEPTED 22 March 2024  \nPUBLISHED 04 April 2024  \nCITATION  \nYan S, He Y, Zhu Y, Ye W, Chen Y, Zhu C, Zhan Fand Ma Z (2024), Human patient derived organoids: an emerging precision medicine model for gastrointestinal cancer research. Front. Cell Dev. Biol. 12:1384450 .  \ndoi: 10.3389/fcell.2024.1384450  \nCOPYRIGHT  \n© 2024 Yan, He, Zhu, Ye, Chen, Zhu, Zhan and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nHuman patient derived organoids: an emerging precision medicine model for gastrointestinal cancer research  \nSicheng Yan 1,2, Yuxuan He 1,2, Yuehong Zhu 1,2, Wangfang Ye 1,2, Yan Chen 3, Cong Zhu 3, Fuyuan Zhan 1,2 and Zhihong Ma 1,2*  \n1Huzhou Key Laboratory of Molecular Medicine, Huzhou Central Hospital, The Afﬁliated Central Hospital of Huzhou University, Huzhou, China, 2School of Basic Medicine College, Zhejiang Chinese Medical University, Hangzhou, China, 3Department of Colorectal Surgery, Huzhou Central Hospital, The Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, China  \nGastrointestinal cancers account for approximately one-third of the total global cancer incidence and mortality with a poor prognosis. It is one of the leading causes of cancer-related deaths worldwide. Most of these diseases lack effective treatment, occurring as a result of inappropriate models to develop safe and potent therapies. As a novel preclinical model, tumor patient-derived organoids (PDOs), can be established from patients’ tumor tissue and cultured in the laboratory in 3D architectures. This 3D model can not only highly simulate and preserve key biological characteristics of the source tumor tissue in vitro but also reproduce the in vivo tumor microenvironment through co-culture. Our review provided an overview of the different in vitro models in current tumor research, the derivation of cells in PDO models, and the application of PDO model technology in gastrointestinal cancers, particularly the applications in combination with CRISPR/Cas9 gene editing technology, tumor microenvironment simulation, drug screening, drug development, and personalized medicine. It also elucidates the ethical status quo of organoid research and the current challenges encountered in clinical research, and offers a forward-looking assessment of the potential paths for clinical organoid research advancement.  \nKEYWORDS  \ngastrointestinal cancers, organoid, 3D model, CRISPR/cas9, personalized medicine  \n1 Introduction  \nGastrointestinal (GI) tumors are a common group of malignant tumors, including gastric, colorectal, esophageal, pancreatic, hepatocellular, and cholangiocellular cancers (Liu et al., 2022; Shi et al., 2022). Among them, gastric cancer (GC) and colorectal cancer (CRC) are the most prominent GI cancers (Weng et al., 2019; Huang et al., 2023) . According to the global Cancer Statistics in 2020, there were about 19.3 million new cancer cases worldwide, including more than one million new cases of GC and 769,000 deaths. Globally, GC ranks ﬁfth in incidence and fourth in mortality (Xia and Aadam, 2022) . CRC is the third most common cause of cancer mortality worldwide, with more than 1.85 million cases and 850,000 deaths ann","cbCaihCIIJW33MTQ","https://ap.wps.com/l/cbCaihCIIJW33MTQ","pdf",1443761,23,"English","# Introduction\n# Tumor patient-derived organoids (PDOs) as a preclinical model\n## Derivation and in vitro capabilities\n## Applications in gastrointestinal cancers\n# CRISPR/Cas9 and microenvironment simulation\n## Drug screening and drug development\n## Personalized medicine and clinical translation\n# Ethics and current challenges","[{\"question\":\"Why are gastrointestinal cancers difficult to treat with current approaches?\",\"answer\":\"Many gastrointestinal cancer cases have a poor prognosis and lack effective treatments, partly because established preclinical models are not sufficiently appropriate for developing safe and potent therapies.\"},{\"question\":\"What are tumor patient-derived organoids (PDOs) and what do they enable?\",\"answer\":\"PDOs are derived from patients’ tumor tissue and cultured as 3D architectures. They preserve key biological characteristics of the original tumor and can recreate elements of the tumor microenvironment through co-culture.\"},{\"question\":\"How are PDOs used alongside CRISPR/Cas9 and for drug-related research?\",\"answer\":\"The review highlights applications of PDO technology in gastrointestinal cancers, including combining with CRISPR/Cas9 gene editing, simulating the tumor microenvironment, and supporting drug screening and drug development.\"}]","Human patient derived organoids - an emerging precision medicine model for gastrointestinal cancer research | PDF",1790040416,58,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e969806da3a954586fc780205e69c0dc.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/505610ef5137900ae1ea988e5898439b.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e31513aa93cabb87a73c663d830bfd2.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/153ac092b5ceffaa8e0bc39b8204a1c2.webp",980,1385]